Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Toshiba American Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Formation of a new management team for the company's Ultrasound Business Unit has been completed, Toshiba states. Members of the management team include: T. Michael McLean, vice president, Ultrasound Business Unit, who was most recently vice president for Johnson & Johnson Clinical Diagnostics; Eli Wisner, director, Ultrasound Sales, who was previously general manager for Percusurge; and Ross Heaton, director, Ultrasound Marketing, who was senior vice president of marketing and sales for Perception Ultrasound International. The company says formation of this team "comes at a particularly important time as Toshiba launches its PowerVision 6000 system." Toshiba launched the PowerVision 6000 May 19 at the Leading Edge conference in Atlantic City, New Jersey. The mobile, 256-channel digital system offers high-end capabilities at a mid-range price, the firm claims...

You may also be interested in...

QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts